Denteric Pty Ltd
- Biotech or pharma, therapeutic R&D
Clinical stage biotech developing therapeutic treatments to treat chronic inflammatory diseases caused by the oral bacterium Phorphyomonas gingivalis. Phase I safety studies have shown GPV381 to be safe and well tolerated. The lead indication is periodontitis followed by Alzheimer's disease. Recombinant protein and mRNA platforms are available.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}